VBI Vaccines Profile

USD 0.11  2.74%

VBI Vaccines exotic insider transaction detected

VBI Vaccines Inc insider trading alert for general transaction of option (right to buy common shares) by Dewilde Michel, the corporate stakeholder, on February 21, 2018. This event was filed by Vbi Vaccines Inc with SEC on 2017-04-27. Initial filing of beneficial ownership - SEC Form 3 [view details]   

VBI Vaccines Summary

VBI Vaccines Inc (VBIV) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 98 people. VBI Vaccines is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 256.96 M. VBI Vaccines Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 64.08 M outstanding shares of which 653.63 K shares are at this time shorted by private and institutional investors with about 1.91 trading days to cover. VBI Vaccines Inc. currently holds about 67.69 M in cash with (31.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06.
Check VBI Vaccines Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected VBI Vaccines Inc Income Statement Over Time

Earning Before Interest and Taxes EBIT    Net Income    Revenues    

Key Fundamentals

VBI Vaccines Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 85% 
Equity ratings for VBI Vaccines Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets exchange. It employs 98 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameVBI Vaccines Inc
CEO, DirectorJeff BaxterView All
Thematic ClassificationPharmaceutical ProductsView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
Business Address222 Third Street
ExchangeNasdaq Capital Markets
Contact Number617 830 3031
CurrencyUSD - US Dollar


VBI Vaccines Analyst Recommendations
Target PriceAdvice# of Analysts
8.5Strong Buy2Odds
VBI Vaccines Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
VBI Vaccines Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


VBI Vaccines Earnings Estimates
VBI Vaccines Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


VBI Vaccines Corporate Directors
Ran Nussbaum Director
Tomer Kariv Director
Adam Logal Director